




Instance: composition-en-de5eecf9e44a37927bab25be6edb8bcb
InstanceOf: CompositionUvEpi
Title: "Composition for fareston Package Leaflet"
Description:  "Composition for fareston Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/96/004/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpde5eecf9e44a37927bab25be6edb8bcb)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - fareston"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Fareston is and what it is used for</li>
<li>What you need to know before you take Fareston</li>
<li>How to take Fareston</li>
<li>Possible side effects</li>
<li>How to store Fareston</li>
<li>Contents of the pack and other information</li>
</ol> </div>"""   
          

* section[=].section[+]
  * title =  "1. What fareston is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What fareston is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Fareston contains the active substance toremifene, an anti-estrogen. Fareston is used for the treatment 
of a certain type of breast tumour in women who have had their menopause.</p> </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take fareston"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take fareston"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <h2>Do not take Fareston</h2>
<p>if you are allergic to toremifene or any of the other ingredients of this medicine (listed in 
section 6).
-
if you have a thickening of the womb lining
-
if you have severe liver problems
-
if you were born with or have had any condition which causes certain abnormal changes in the 
electrical recording of the heart (electrocardiogram or ECG)
-
if you have a salt imbalance in the blood, especially low concentrations of potassium in the 
blood (hypokalaemia) which are currently not corrected by treatment
-
if you have a very slow heart rate (bradycardia)
-
if you have a heart failure
-
if you have a history of abnormal heart rhythms (arrhythmias)
-
if you are taking other medicines that may affect your heart (see section 2 Other medicines and 
Fareston). 
This is because Fareston can affect your heart by delaying the conduction of electrical signals 
within your heart (prolongation of QT-interval).
Warnings and precautions
Talk to your doctor or pharmacist before taking Fareston:
-
if you have unstable diabetes 
-
if your general well-being is severely deteriorated
-
if you have previously had a condition in which blood clots formed in blood vessels, for 
example in your lungs (lung embolism) or in the veins of your legs (deep vein thrombosis).
DNO 090017ff8067d83a
In-Progress
 /  27.3
Confidential
18 / DNO 090017ff8067d83a
Reviewed
 /  27.3
Confidential
18 / DNO 090017ff8067d83a
Approved
 /  28.0
Confidential
18 / -
if you experience an abnormal heart rhythm whilst taking Fareston. Your doctor may advise 
you to stop taking Fareston and perform a medical test to see how your heart is working (ECG).
(see section 2 Do not take Fareston)
-
if you have any heart condition, including chest pain (angina)
-
if your cancer has spread to the bones (bone metastasis) as calcium blood levels may increase at 
the beginning of treatment with Fareston. Your doctor will conduct regular medical check-ups.
-
if you have been told by your doctor that you have an intolerance to certain sugars, like lactose 
(see section 2 Fareston contains lactose).
You should have gynaecological examinations before you start treatment with Fareston and at least 
once a year following the start of treatment with Fareston. Your doctor will conduct regular medical 
check-ups if you have high blood pressure, diabetes, have taken hormone replacement therapy or if
you are obese (BMI over 30). 
Other medicines and Fareston
Tell your doctor if you are taking, have recently taken or might take any other medicines. The dose of 
some of these may have to be adjusted while you are on Fareston. In particular please tell your doctor 
if you are taking any of the following:
-
water tablets (diuretics of thiazide type)
-
medicines to prevent blood clotting such as warfarin 
-
medicines used to treat epilepsy such as carbamazepine, phenytoin, phenobarbital
-
medicines used to treat fungal infections such as ketoconazole, itraconazole, voriconazole, 
posaconazole
-
medicines used to treat bacterial infections (antibiotics) such as erythromycin, clarithromycin
and telithromycin
-
medicines used to treat viral infection such as ritonavir and nelfinavir.
Do not take Fareston together with the following medicines as there is an increased risk that your 
heartbeat may be altered (see section 2 Do not take Fareston):
-
medicines used to treat abnormal heart rhythm (antiarrhythmics); such as quinidine, 
hydroquinidine, disopyramide, amiodarone, sotalol, dofetilide and ibutilide
-
medicines used to treat mental and behavioral disorders (neuroleptics); such as phenothiazines, 
pimozide, sertindole, haloperidol and sultopride
-
medicines used to treat infections (antimicrobials); such as moxifloxacin, erythromycin 
(infusion) pentamidine and antimalarials (particularly halofantrine)
-
certain medicines to treat allergies; such as terfenadine, astemizole and mizolastine
-
others; cisapride, intravenous vincamine, bepridil, diphemanil. 
If you are admitted to the hospital or if you are prescribed a new medicine, please tell your doctor that 
you are taking Fareston.
Pregnancy and breast-feeding
Do not use Fareston during pregnancy or breast feeding.
Driving and using machines
Fareston has no influence on the ability to drive and use machines.
Fareston contains lactose
Fareston contains 28.5 mg lactose (as monohydrate) per tablet. If you have been told by your doctor 
that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.
Other excipients
This medicine contains less than 1 mmol (23 mg) sodium per tablet that is to say essentially  sodium-
free .
DNO 090017ff8067d83a
In-Progress
 /  27.3
Confidential
19 / DNO 090017ff8067d83a
Reviewed
 /  27.3
Confidential
19 / DNO 090017ff8067d83a
Approved
 /  28.0
Confidential
19 / </p> </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take fareston"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take fareston"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist 
if you are not sure. The usual dose is one 60 mg tablet taken orally, once daily. Fareston can be taken 
with or without food.
If you take more Fareston than you should
Contact your doctor, pharmacist or the nearest hospital immediately. Symptoms of overdose may be 
dizziness and headache.
If you forget to take Fareston
If you miss one dose take the next tablet as usual and continue treatment as recommended. Do not 
take a double dose to make up for a forgotten tablet. If you have missed several doses, please inform 
your doctor and follow his instructions.
If you stop taking Fareston
The treatment with Fareston should only be stopped when advised by your doctor.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p> </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.
Very common side effects (may affect more than 1 in 10 people ):
-
hot flushes, sweating.
Common side effects (may affect up to 1 in 10 people ):
-
fatigue, dizziness, depression
-
nausea (feeling sick), vomiting
-
rash, itching, oedema (swelling)
-
uterine bleeding, white discharge.
Uncommon side effects (may affect up to 1 in 100 people):
-
headache, sleep disorders
-
weight increase, constipation, loss of appetite
-
thickening of the lining of the womb (endometrial hypertrophy)
-
blood clot for example in the lung (thromboembolic events)
-
shortness of breath.
Rare side effects (may affect up to 1 in 1,000 people):
-
a feeling of spinning (vertigo)
-
growth on the lining of the womb (endometrial polyps)
-
increase in liver enzymes (increase of liver transaminases).
Very rare side effects (may affect up to 1 in 10,000 people):
-
changes in the lining of the uterus (endometrium), cancer of the lining of the womb 
(endometrial cancer)
-
hair loss (alopecia)
-
cloudiness of the eye surface (transient corneal opacity)
-
yellowing of the skin or whites of the eyes (jaundice).
Frequency not known (cannot be estimated from the available data):
-
low number of white blood cells, which are important in fighting infection (leukopenia)
-
low number of red blood cells (anaemia)
DNO 090017ff8067d83a
In-Progress
 /  27.3
Confidential
20 / DNO 090017ff8067d83a
Reviewed
 /  27.3
Confidential
20 / DNO 090017ff8067d83a
Approved
 /  28.0
Confidential
20 / -
low number of platelets (thrombocytopenia)
-
inflammation of the liver (hepatitis).
You should contact your doctor immediately if you notice any of the following:
-
swelling or tenderness in your calf
-
unexplained shortness of breath or sudden chest pain
-
vaginal bleeding or changes in vaginal discharge.
Fareston causes certain abnormal changes in the electrical recording of the heart (electrocardiogram 
or ECG). See section 2 Warnings and precautions.
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety 
of this medicine.</p> </div>"""      
        
* section[=].section[+]
  * title = "5. How to store fareston"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store fareston"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the label. The expiry date refers to 
the last day of that month.
This medicine does not require any special storage conditions.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment.</p> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <h2>What Fareston contains</h2>
<h2>The active substance is toremifene; each tablet contains 60 mg (as citrate).</h2>
<p>The other ingredients are maize starch, lactose monohydrate, povidone, sodium starch 
glycolate, microcrystalline cellulose, colloidal anhydrous silica and magnesium stearate.
What Fareston looks like and contents of the pack
White, round, flat, bevelled edge tablet with TO 60 on one side.
30 and 100 tablets. Not all pack sizes may be marketed.
Marketing Authorisation Holder
Orion Corporation
Orionintie 1
FI-02200 Espoo
Finland
Manufacturer
Orion Corporation Orion Pharma
Joensuunkatu 7
FI-24100 Salo
Finland
For any information about this human medicinal product, please contact the local representative of the 
marketing authorisation holder.
DNO 090017ff8067d83a
In-Progress
 /  27.3
Confidential
21 / DNO 090017ff8067d83a
Reviewed
 /  27.3
Confidential
21 / DNO 090017ff8067d83a
Approved
 /  28.0
Confidential
21 / Belgi /Belgique/Belgien
Orion Corporation
T l/Tel: +358 10 4Lietuva
Orion Corporation
Tel: +358 10 4 
Orion Pharma Poland Sp. z o.o.
Tel: + 48 22 8 333 Luxembourg/Luxemburg
Orion Corporation
T l/Tel: +358 10 4 esk  republika
Orion Corporation
Tel: +358 10 4Magyarorsz g
Orion Corporation
Tel.: +358 10 4Danmark
Orion Corporation
Tlf: +358 10 4Malta
Orion Corporation
Tel: +358 10 4Deutschland
Orion Corporation
Tel: +358 10 4Nederland
Orion Corporation
Tel: +358 10 4Eesti
Orion Corporation
Tel: +358 10 4Norge
Orion Corporation
Tlf: +358 10 4 
Orion Corporation
 : +358 10 4 sterreich
Orion Corporation
Tel: +358 10 4Espa a
Orion Corporation
Tel: +358 10 4Polska
Orion Corporation
Tlf: +358 10 4France
Orion Pharma
T l: +33 (0) 1 85 18  00 Portugal
Orion Corporation
Tel: +358 10 4Hrvatska
Orion Corporation
Tel.: +358 10 4Rom nia
Orion Pharma Poland Sp. z o.o.
Tel: + 48 22 8 333 Ireland
Orion Corporation
Tlf: +358 10 4Slovenija
Orion Corporation
Tel: +358 10 4 sland
Orion Corporation
S mi: +358 10 4Slovensk  republika
Orion Corporation
Tel: +358 10 4Italia
Orion Pharma S.r.l.
Tel: + 39 02 67876Suomi/Finland
Orion Corporation
Puh./Tel: +358 10 4DNO 090017ff8067d83a
In-Progress
 /  27.3
Confidential
22 / DNO 090017ff8067d83a
Reviewed
 /  27.3
Confidential
22 / DNO 090017ff8067d83a
Approved
 /  28.0
Confidential
22 /<br />
Orion Corporation
 : +358 10 4Sverige
Orion Pharma AB
Tel: +46 8 623 6Latvija
Orion Corporation
Tel: +358 10 4United Kingdom (Northern Ireland)
Orion Corporation
Tel: +358 10 4This leaflet was last revised in 
Detailed information on this medicine is available on the European Medicines Agency web site: </p> </div>"""      



Instance: composition-da-de5eecf9e44a37927bab25be6edb8bcb
InstanceOf: CompositionUvEpi
Title: "Composition for fareston Package Leaflet"
Description:  "Composition for fareston Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/96/004/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpde5eecf9e44a37927bab25be6edb8bcb)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - fareston"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. INDLÆGSSEDDEL"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. INDLÆGSSEDDEL"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Indlægsseddel: Information til brugeren"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Indlægsseddel: Information til brugeren"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "Oversigt over indlægssedlen"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Oversigt over indlægssedlen"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen
1. Virkning og anvendelse
2. Det skal du vide, før du begynder at tage Fareston
3. Sådan skal du tage Fareston
4. Bivirkninger
5. Opbevaring
6. Pakningsstørrelser og yderligere oplysninger</p> </div>"""   
          

* section[=].section[+]
  * title =  "1. Virkning og anvendelse"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. Virkning og anvendelse"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Fareston indeholder det aktive stof toremifen, et antiøstrogen. Fareston anvendes til behandling af 
visse former for brystkræft hos kvinder efter overgangsalderen.</p> </div>"""   
          

             
* section[=].section[+]
  * title = "2. Det skal du vide, før du begynder at tage  fareston"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. Det skal du vide, før du begynder at tage  fareston"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <h2>Tag ikke Fareston:</h2>
<p>hvis du er allergisk over for toremifen eller et af de øvrige indholdsstoffer i Fareston (angivet i 
punkt 6)
-
hvis du har en fortykkelse af livmoderslimhinden
-
hvis du har alvorlige leverproblemer
-
hvis du er født med eller har oplevet tilfælde med visse unormale forandringer i hjertets 
elektriske aktivitet (ses i elektrokardiogram (ekg))
-
hvis du har en forstyrrelse i blodets saltbalance, især lavt indhold af kalium i blodet 
(hypokaliæmi), som endnu ikke er blevet behandlet
-
hvis du har en meget langsom hjerterytme (puls)
-
hvis du har hjertesvigt
-
hvis du tidligere har haft unormal hjerterytme (arytmi)
-
hvis du tager andre lægemidler, som kan påvirke dit hjerte (se punkt 2 "Brug af anden medicin
sammen med Fareston")
Dette skyldes, at Fareston kan påvirke dit hjerte ved at forsinke overledningen af de elektriske 
signaler i dit hjerte (forlængelse af QT-intervallet)
Advarsler og forsigtighedsregler
Kontakt lægen eller apotekspersonalet, før du tager Fareston:
-
hvis du har ustabil diabetes (sukkersyge)
-
hvis dit helbred er alvorligt forringet 
-
hvis du tidligere har haft en tilstand, hvor der dannes blodpropper i dine vener, f.eks. i lungerne
(lungeemboli ) eller i venerne i dine ben (dybe venetrombose)
19
-
hvis du oplever en unormal hjerterytme, mens du tager Fareston. Din læge vil muligvis råde dig 
til at stoppe med at tage Fareston og få undersøgt, hvordan dit hjerte fungerer (ekg) (se punkt 2 
"Tag ikke Fareston")
-
hvis du har nogen form for hjertelidelse herunder brystsmerter (angina)
-
hvis din kræft har spredt sig til knoglerne (knoglemetastaser), da calciumniveauet i dit blod kan 
stige i begyndelsen af behandlingen med Fareston. Din læge vil kontrollere dig regelmæssigt.
-
hvis din læge har fortalt dig, at du ikke kan tåle visse sukkerarter såsom lactose (se punkt 2 
"Fareston indeholder lactose"
Du skal have foretaget en gynækologisk undersøgelse, før du påbegynder behandlingen med Fareston 
og derefter mindst 1 gang om året. Din læge vil kontrollere dig regelmæssigt, hvis du har højt 
blodtryk, sukkersyge, har taget hormonerstatnings-behandling, eller hvis du er overvægtig (BMI over 
30).
Brug af anden medicin sammen med Fareston
Fortæl det altid til lægen eller apotekspersonalet, hvis du bruger anden medicin eller har gjort det for 
nylig. Dosis af noget af denne medicin skal måske reguleres, mens du tager Fareston. Du skal især 
fortælle det til lægen, hvis du tager følgende medicin:
-
vanddrivende medicin (af thiazidtypen),
-
medicin for at modvirke blodpropper såsom warfarin,
-
medicin til behandling af epilepsi såsom carbamazepin, phenytoin, phenobarbital,
-
medicin til behandling af svampeinfektioner såsom ketoconazol, itraconazol, voriconazol, 
posaconazol,
-
medicin til behandling af bakterieinfektioner såsom erythromycin, clarithromycin og 
telithromycin
-
medicin til behandling af virusinfektioner såsom ritonavir og nelfinavir.
Du må ikke tage Fareston sammen med følgende medicin, da der er en øget risiko for, at det kan 
ændre din hjerterytme (se punkt 2 "Tage ikke Fareston"):
-
medicin til behandling af rytmeforstyrrelser såsom quinidin, hydroquinidin, disopyramid, 
amiodaron, sotalol, dofetilid og ibutilid
-
medicin til behandling af psykiske og adfærdsmæssige lidelser (antipsykotika) såsom
phenothiaziner, pimozid, sertindol, haloperidol og sultoprid
-
lægemidler til behandling af infektioner (antibiotika) såsom moxifloxacin, erythromycin i en 
blodåre, pentamidin og lægemidler mod malaria (især halofantrin)
-
visse lægemidler til behandling af allergier såsom terfenadin, astemizol og mizolastin
-
andre; cisaprid, vincamin i en blodåre, bepridil, diphemanil.
Hvis du bliver indlagt på hospitalet, eller hvis du får ordineret en ny slags medicin, skal du fortælle 
lægen, at du er i behandling med Fareston.
Graviditet og amning
Du må ikke tage Fareston under graviditet eller amning.
Trafik og arbejdssikkerhed
Fareston har ingen indflydelse på evnen til at føre motorkøretøj og betjene maskiner.
Fareston indeholder lactose
Fareston indeholder 28,5 mg lactose (som monohydrat) pr. tablet. Kontakt lægen, før du tager dette 
lægemiddel, hvis lægen har fortalt dig, at du ikke tåler visse sukkerarter.
Andre hjælpestoffer
Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr. tablet, dvs. det er i det 
væsentlige natriumfrit.
20</p> </div>"""   
                    
* section[=].section[+]
  * title =  "3. Sådan skal du tage fareston"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. Sådan skal du tage fareston"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens anvisning. Er du i tvivl, så spørg lægen eller
apotekspersonalet. Den sædvanlige dosis er én 60 mg tablet indtaget oralt, én gang dagligt. Fareston 
kan tages sammen med eller uden mad.
Hvis du har taget for mange Fareston 
Kontakt straks lægen, skadestuen eller apotekspersonalet, hvis du har taget mere Fareston, end der 
står i denne information eller mere end lægen har foreskrevet. Symptomer på en overdosis kan være 
svimmelhed og hovedpine.
Hvis du har glemt at tage Fareston
Hvis du glemmer en dosis, skal du tage den næste tablet som sædvanligt og fortsætte behandlingen, 
som anbefalet. Du må ikke tage en dobbeltdosis som erstatning for den glemte dosis. Hvis du har 
glemt flere doser, skal du informere din læge og følge lægens instruktioner.
Hvis du holder op med at tage Fareston
Behandling med Fareston bør kun ophøre, hvis din læge har anbefalet det.
Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om.</p> </div>"""         

        
* section[=].section[+]
  * title = "4. Bivirkninger"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Bivirkninger"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger.
Meget almindelige bivirkninger (kan forekomme hos flere end 1 ud af 10 personer)
-
hedeture, svedtendens.
Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 personer)
-
træthed, svimmelhed, depression
-
kvalme, opkastning
-
udslæt, kløe, væskeansamlinger (ødemer)
-
blødning fra livmoderen, hvidt udflåd.
Ikke almindelige bivirkninger (kan forekomme hos op til 1 ud af 100 personer)
-
hovedpine, søvnproblemer
-
vægtstigning, forstoppelse, appetitløshed
-
fortykkelse af livmoderslimhinden
-
dannelse af blodpropper f.eks. i lungerne 
-
kortåndethed.
Sjældne bivirkninger (kan forekomme hos op til 1 ud af 1.000 personer)
-
følelse af, at det snurrer rundt (svimmelhed)
-
udvoksninger på livmoderslimhinden (polypper i livmoderens slimhinde)
-
forhøjede leverenzymer i blodet (forhøjede aminotransferaser).
Meget sjældne bivirkninger (kan forekomme hos op til 1 ud af 10.000 personer)
-
ændringer i livmoderslimhinden (endometriet)
-
kræft i livmoderslimhinden
-
hårtab
-
forbigående uklarhed i hornhinden
-
gulfarvning af huden og det hvide i øjnene (gulsot).
Hyppighed ikke kendt (kan ikke estimeres ud fra forhåndenværende data)
21
-
lavt antal af hvide blodlegemer, der er vigtige til bekæmpelse af infektion (leukopeni)
-
lavt antal af røde blodlegemer (blodmangel)
-
lavt antal af blodplader (tendens til blødning)
-
leverbetændelse (hepatitis).
Du skal straks kontakte din læge, hvis du mærker et af følgende symptomer: 
-
hævelse eller ømhed i læggen
-
uforklarlig kortåndethed eller smerter i brystet
-
blødning fra skeden eller forandringer i udflåd.
Fareston forårsager visse unormale forandringer i hjertets elektriske aktivitet (ses i elektrokardiogram
(ekg)). Se punkt 2 "Advarsler og forsigtighedsregler).
Indberetning af bivirkninger
Hvis du oplever bivirkninger, bør du tale med din læge eller apotekspersonalet. Dette gælder også 
mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også 
indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i
Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information 
om sikkerheden af dette lægemiddel.</p> </div>"""      
        
* section[=].section[+]
  * title = "5. Opbevaring"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. Opbevaring"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn.
Brug ikke lægemidlet efter den udløbsdato, der står på etiketten. Udløbsdatoen er den sidste dag i den 
nævnte måned.
Dette lægemiddel kræver ingen særlige forholdsregler vedrørende opbevaringen.
Spørg på apoteket, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke smide 
medicinrester i afløbet eller, toilettet eller skraldespanden.</p> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Pakningsstørrelser og yderligere oplysninger"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Pakningsstørrelser og yderligere oplysninger"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <h2>Fareston indeholder:</h2>
<h2>Aktivt stof: toremifen: Hver tablet indeholder 60 mg (som citrat).</h2>
<p>Øvrige indholdsstoffer: majsstivelse, lactosemonohydrat, povidon, natriumstivelsesglycolat,
mikrokrystallinsk cellulose, kolloid vandfri sillica og magnesiumstearat.
Udseende og pakningsstørrelser
Hvid, rund, flad tablet med skrå kanter og mærket TO 60 på den ene side.
30 og 100 tabletter. Ikke alle pakningsstørrelser er nødvendigvis markedsført.
Indehaver af markedsføringstilladelsen
Orion Corporation
Orionintie 1
FI-02200 Espoo
Finland
Fremstiller
Orion Corporation Orion Pharma
Joensuunkatu 7
FI-24100 Salo
Finland
22
Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale
repræsentant for indehaveren af markedsføringstilladelsen:
België/Belgique/Belgien
Orion Corporation
Tél/Tel: +358 10 4261
Lietuva
Orion Corporation
Tel: +358 10 4261
България
Orion Pharma Poland Sp. z o.o.
Tel: + 48 22 8 333 177
Luxembourg/Luxemburg
Orion Corporation
Tél/Tel: +358 10 4261
Česká republika
Orion Corporation
Tel: +358 10 4261
Magyarország
Orion Corporation
Tel.: +358 10 4261
Danmark
Orion Corporation
Tlf: +358 10 4261
Malta
Orion Corporation
Tel: +358 10 4261
Deutschland
Orion Corporation
Tel: +358 10 4261
Nederland
Orion Corporation
Tel: +358 10 4261
Eesti
Orion Corporation
Tel: +358 10 4261
Norge
Orion Corporation
Tlf: +358 10 4261
Ελλάδα
Orion Corporation
Τηλ: +358 10 4261
Österreich
Orion Corporation
Tel: +358 10 4261
España
Orion Corporation
Tel: +358 10 4261
Polska
Orion Corporation
Tlf: +358 10 4261
France
Orion Pharma
Tél: +33 (0) 1 85 18  00 00
Portugal
Orion Corporation
Tel: +358 10 4261
Hrvatska
Orion Corporation
Tel.: +358 10 4261
România
Orion Pharma Poland Sp. z o.o.
Tel: + 48 22 8 333 177
Ireland
Orion Corporation
Tlf: +358 10 4261
Slovenija
Orion Corporation
Tel: +358 10 4261
Ísland
Orion Corporation
Sími: +358 10 4261
Slovenská republika
Orion Corporation
Tel: +358 10 4261
23
Italia
Orion Pharma S.r.l.
Tel: + 39 02 67876111
Suomi/Finland
Orion Corporation
Puh./Tel: +358 10 4261
Κύπρος
Orion Corporation
Τηλ: +358 10 4261
Sverige
Orion Pharma AB
Tel: +46 8 623 6440
Latvija
Orion Corporation
Tel: +358 10 4261
United Kingdom (Northern Ireland)
Orion Corporation
Tel: +358 10 4261
Denne indlægsseddel blev senest ændret
Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs
hjemmeside http://www.ema.europa.eu.</p> </div>"""      





                    
Instance: bundlepackageleaflet-en-de5eecf9e44a37927bab25be6edb8bcb
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for fareston Package Leaflet for language en"
Description: "ePI document Bundle for fareston Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-de5eecf9e44a37927bab25be6edb8bcb"
* entry[0].resource = composition-en-de5eecf9e44a37927bab25be6edb8bcb

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpde5eecf9e44a37927bab25be6edb8bcb"
* entry[=].resource = mpde5eecf9e44a37927bab25be6edb8bcb
                            
                    
Instance: bundlepackageleaflet-da-de5eecf9e44a37927bab25be6edb8bcb
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for fareston Package Leaflet for language da"
Description: "ePI document Bundle for fareston Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-de5eecf9e44a37927bab25be6edb8bcb"
* entry[0].resource = composition-da-de5eecf9e44a37927bab25be6edb8bcb

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpde5eecf9e44a37927bab25be6edb8bcb"
* entry[=].resource = mpde5eecf9e44a37927bab25be6edb8bcb
                            
                    



Instance: mpde5eecf9e44a37927bab25be6edb8bcb
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Fareston 60 mg tablets"
Description: "Fareston 60 mg tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/96/004/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Fareston 60 mg tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: de5eecf9e44a37927bab25be6edb8bcbListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "fareston"

* status = #current
* mode = #working

* title = "List of all ePIs associated with fareston"

* subject = Reference(mpde5eecf9e44a37927bab25be6edb8bcb)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#fareston "fareston"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry[+]
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-de5eecf9e44a37927bab25be6edb8bcb) // fareston en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry[+]
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-de5eecf9e44a37927bab25be6edb8bcb) // fareston da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-de5eecf9e44a37927bab25be6edb8bcb
InstanceOf: List
Description: "ePI document List for fareston Package Leaflets"

* insert de5eecf9e44a37927bab25be6edb8bcbListRuleset
    